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According to the authors, the guidelines contains the 
most justified principles of diagnostic and therapeutic 
procedures. They should, however, be interpreted in 
the context of the individual clinical situation. Recom-
mendations do not always correspond to the current 
refund rules in force in Poland. In case of doubt, you 
should be sure of the current refund possibilities of 
each procedure.
Epidemiology and aetiology
Skin melanomas are malignant neoplasms deriving 
from neuroendocrine melanocytic cells. Melanoma are 
relatively rare in Poland — a standardised incidence 
rate reaches about 5/100,000, which represents 3100 new 
melanoma cases per year during the last few years 
(about 1400 men and about 1700 women). However, 
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the incidence rate of melanoma is increasing rapidly 
compared to other neoplasms. A threefold increase of 
melanoma morbidity has been observed in Poland dur-
ing the years 1980 to 2010. The median age at diagnosis 
is similar for both sexes and equals about 50 years. The 
standardised mortality rate reaches 2.3/100,000 men 
and 1.5/100,000 women, which represents, during the 
last years, respectively, about 700 and 630 melanoma 
related deaths [1, 2].
The influence of the natural ultraviolet radiation 
(solar rays) and artificial radiation (e.g. tanning beds, 
solarium), permanent mechanical or chemical irrita-
tion, low content of pigment in the skin, and genetic 
predispositions (e.g. familial atypical mole syndrome; 
FAMS) constitute risk factors of melanomas.
Skin melanoma has an unique chance to be cured 
due to its localisation, which enables early identification 
of the primary site (microstaging I — excisional biopsy 
of the primary lesion) and of the metastases to the 
locoregional lymph nodes (microstaging II — sentinel 
nodes biopsy).
In about 80% of patients, cutaneous melanoma is 
a limited, local disease, while a loco-regional advanced 
or metastatic disease is primarily diagnosed in, respec-
tively, 15% and 5% of patients. Progress in the adju-
vant and palliative therapy of patients with metastatic 
melanoma is still unsatisfactory. The five-year overall 
survival rates reach in early stages of melanoma 70–95% 
as well as 20–70% and 5–10% in regionally advanced 
and metastatic disease. 
The crucial recommendation is to treat a melanoma 
patient with a multidisciplinary team formed by specialists 
experienced in diagnosing and treating melanoma [3, 4]. 
Diagnostics 
Clinical symptoms
Skin melanomas may be suspected in both de 
novo skin changes and in alterations of pre-existing 
moles. There are some attempts to create diagnostic 
systems based on clinical symptoms (Table 1). The 
most popular is the American mnemonic, clinical 
system called ABCD(E), actually used mostly with 
educational intention because it is useful only in iden-
tification of some melanomas, mostly of the superficial 
spreading melanomas and of the majority of advanced 
melanomas. However, this system cannot be used as 
a diagnostic (screening) tool in daily clinical practice. 
A clinical ABCD(E) system does not permit appropriate 
qualification of about 50% of melanomas (especially 
including the early stages of skin melanomas with dia-
meter < 5 mm, nodular melanoma usually without pa-
rameter C — heterogeneity of colour and B — irregular 
border as well as amelanotic melanomas and changes 
of the hairy skin of the head surface) [1]. 
Thin melanomas (< 1 mm of thickness according to 
Breslow scale) are usually identified during the medical 
examination, whereas very rarely by a patient him/herself 
or by his/her relatives. 
Diagnostics
Medical history should include questions concerning 
skin condition (information concerning changes of the 
pre-existing skin moles or the appearance of new moles) 
and risk factors of cutaneous melanoma (e.g. sunburn, 
use of tanning beds, melanomas in relatives). We should 
stress that skin examination is a crucial method of detect-
ing skin melanomas and should be performed by each 
physician during the ambulatory visit or hospitalisation 
of any patient. The major rule of the visual inspection 
is to evaluate the total skin surface in appropriate light-
ing, also including the hard-to-reach areas (head, feet, 
interdigital spaces, urogenital, and perianal areas).
Dermatoscopy (dermoscopy) is a recommended 
tool used in initial diagnostics. Due to dermatoscopy 
the sensitivity of the diagnostics may be improved 
by 30%. The simplest dermatoscopic technique (the 
so-called three-point dermatoscopic scale) is based on 
clinical suspicion of a skin melanoma in the case when 
Table 1. American ABCD(E) system, which enables the initial identification of a part of melanomas based on a clinical 
examination without use of any supplementary diagnostic methods
ABCD system
A — asymmetry (a melanoma in contrast to usually round or ellipsoidal benign changes, is asymmetrical in relation to any 
axis. Melanoma presents as an uneven change composed of elevations called ‘islands’)
B — borders (irregular and unravelled)
C — colour [the presence of more than one colour (from bright brown to black or steel blue) or the uneven distribution of colour, 
often with spotted distribution of the pigment. (especially well visible on the dermatoscopy)]
D — diameter (diameter > 5 mm or dynamics of the morphological sizes in a tumour)
E — elevation or evolution [elevation of surface over the level of the change surrounding epidermis. Thin melanomas 
(thickness ≤ 1 mm according to Breslow scale) do not form a palpable node compared to a normal skin surrounding the lesion; 
increase of the diameter (extension or evolution) of the primary change is more significant than its elevation]
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two of the following three criteria are present: 1) asym-
metric distribution of the structures within the change, 2) 
atypical pigmentation network, and 3) blue-white veil. The 
sensitivity of this diagnostic method reaches 96.3% and 
specificity 94.2%. Other methods of dermatoscopic analy-
sis including the dermatoscopic method ABCD, pattern 
analysis, seven-point scale, Menzies’s method, or CASH 
(colour, architecture, symmetry, homogeneity) algorithm 
are characterised by similar sensitivity and slightly higher 
specificity. It should be stressed that the presented derma-
toscopic evaluation systems cannot be used to assess lesions 
placed in ‘special locations’ including changes of palms and 
soles of the feet, the hairy skin of the head surface, the 
skin of the face, mucosa of the mouth, and the external 
sex organs. In such cases it is necessary to apply dermato-
scopic algorithms, dedicated to the character of the skin of 
each localisation. In the case of atypical mole syndrome it 
may be useful to collect photographic records of a lesion 
or of the total skin surface (total body photography) and 
to compare taken pictures and observed skin lesions in 
consecutive time sequences. There are some systems that 
automatically compare dermatoscopic pictures taken in 
different time sequences; however, they are not commonly 
used due to their technological limitations. 
An initial dermatoscopic diagnosis may by verified by 
use of the confocal reflection microscopy. In some justified 
cases when an excisional biopsy cannot be performed (e.g. 
when melanoma is suspected in the area of the extensive 
congenital moles in small children), it is possible to per-
form a dermatoscopy-guided biopsy in order to obtain 
a sample for further histopathological examination. 
Histopathologic examination of the whole excised 
mole is crucial for diagnosing a skin melanoma. Proce-
dures other than excisional biopsy (micrograding I) do 
not permit an appropriate diagnosis [III, A].
Once a histopathological diagnosis of a skin mela-
noma has been made a clinical stage tailored therapy 
should be implemented (see below). 
The supplementary diagnostic tests used in clinical 
staging of the melanoma include: essential blood test [pe-
ripheral blood morphology, liver enzymes levels, lactate 
dehydrogenase (LDH) activity], radiologic exam (RTG) of 
the chest in an anteroposterior and in lateral projection as 
well as the ultrasonographic exam of the abdomen and of 
the locoregional lymph nodes. In asymptomatic patients, 
no other supplementary test should be done, including 
computed tomography (CT) and positron emission tomo-
graphy (PET). CT or PET may be considered in patients 
with diagnosed skin melanoma in clinical stage III (espe-
cially if the clinical metastases to the lymph nodes are pre-
sent) or with isolated metastases to the distant organs. In 
the case of the clinical metastases to the inguinal lymph 
nodes it is recommended that CT or magnetic resonance 
imaging (MRI) of the pelvis and abdomen is performed. 
In patients with melanoma metastases from an 
unknown primary site to the lymph nodes or to the 
skin, a primary lesion should be searched for carefully 
(especially on the hairy skin of the head surface and the 
mucosal membranes) and a detailed medical history 
taken (e.g. concerning any cosmetic medicine ablation 
methods applied to any lesion).
Differentiation
The conditions that should be considered in the dif-
ferential diagnostics of the early and locally advanced 
skin melanoma are presented in Table 2.
Histopathological diagnosis — excisional biopsy  
of the skin lesion (microstaging I)
An excisional biopsy of the clinically suspected skin 
lesion is a method of choice because it allows confir-
mation of a microscopic diagnosis of melanoma and 
collection of data concerning the crucial risk factors, 
crucial for planning a further therapeutic approach 
(microstaging III, A) [1, 3–5]. There are no indications 
for prophylactic excision of skin moles that are not 
suspected of being skin melanoma. 
Pathomorphological examination of samples from 
the excisional biopsy consists of macro and microscopic 
assessment of all elements that are required or recom-
mended for examination and inclusion in the histopatho-
logic protocol (http:/www.pol-pat.pl/pliki/files/stand-
ardy_pdf/1.2_czerniak.pdg):
1. Macroscopic assessment 
a. Size of the excited skin section with the lesion 
(three dimensions);
b. Size of the lesion (two dimensions);
c. Pigmentation (homogenous, heterogeneous);
d. Border of the lesion (regular, irregular);
e. Nodule (present, not present);
f. Margins (lateral and deep margin).
2. Microscopic assessment 
 Microscopic features/characteristics that are required 
a. Breslow thickness of infiltration (in millimetres) 
is measured from the top of the granular layer 
of the epidermis, or if the surface is ulcerated 
— from the base of the ulcer, to the deepest 
invasive cell across the broad base of the tumour;
b. The presence or absence of ulceration including 
the whole thickness of the epidermis covering the 
tumour as well as information about the extent 
of ulceration, measured either as the diameter 
or percentage of tumour width;
c. The mitotic count per square millimetre of the 
invasive melanoma (only in a vertical component, 
in the mitotic high-power fields that equates to 
1 mm2, so-called hot spots);
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Table 2. Clinical differential diagnostics of skin melanoma
Early skin melanoma  Nevus pigmentosus, including junction nevus (naevus melanocyticus junctionalis, 
marginalis) and compound nevus (naevus melnocyticus compositus)
 Blue nevus (naevus coeruleus)
 Simple lentigo (lentigo simplex)
 Actinic keratosis or solar keratosis 
 Superficial basal cell carcinoma (carcinoma basocellulare superficiale) 
 Spitz’s naevus
 Tattoo
Locally advanced melanoma  Seborrheic keratosis (verruca seborrhoica, keratosis seborrhoica)
 Dermatofibroma
 Keratoacanthoma
 Pigmented basal cell carcinoma (carcinoma basocellulare pigmentosum)
 Haemangioma 
 Venous extravasation
 Pyogenic granuloma (granuloma pyogenicum) and teleangiectatic granuloma 
(granuloma teleangiectaticum)
 Pigmented hidrocystoma
 Kaposi’s sarcoma 
 Angiomyoneuroma
 Other adnexal tumours, especially pigmented
 Onychomycosis
 Subungual or under cutaneous corn haemangioma 
d. Growth phases [horizontal (radial) — intraepi-
dermal, in situ with microinvasion and sagittal 
(vertical), always skin invasion];
e. Presence or absence of microscopic satellite 
sites (sites composed of melanocytes with dia-
meter > 0.05 mm remoted > 0.3 mm and < 2 cm 
from the invasive component of the primary 
melanoma tumour — parameter N). 
f. Peripheral margin (measured from the in situ to 
the invasive component) and in depth;
g. Clinical stage pT;
Recommended elements:
h. Presence and extend of tumour regression;
i. Clark level of invasion (level I, II, III, IV, V);
j. Histopathologic subtype [superficial spreading 
melanoma (SSM), lentigo maligna melanoma 
(LMM); arising from a lentigo or in a Hutch-
inson age spot, nodular melanoma (NM), acral 
lentiginous melanoma (ALM) — subungual, 
other types — e.g. desmoplastic]; 
k. Cell type (epithelioid, fusiform, small, pleomor-
phic, other); 
l. Presence and grading of the lymphocytic in-
filtration [tumour infiltrating lymphocytes 
(TILs); evaluated only in a vertical component; 
absent, moderate — TILs non-brisk, abundant 
— TILS brisk];
m. Presence or absence of lymph and blood ves-
sel infiltration;
n. Presence or absence of nerve trunk infiltration; 
o. Presence of a mole.
An excisional biopsy is a simple surgical procedure and 
usually may be done in an outpatient clinic. Excision of the 
suspected skin change is done in local infiltration anaesthe-
sia. The lateral excision margin should include 1–2 mm of 
healthy skin. The surgical specimen should include not only 
the whole thickness of the skin but also a superficial layer 
of the adipose tissue. The fascia should not be excised, and 
the wound should be closed by a primary suture. The skin 
should be cut as an ellipse specimen following the lines 
of relaxed skin tension (Fig. 1). Only the cut of the face 
lesion should follow the aesthetic lines. Transversal cuts 
should never be done (on the limb area) because in the 
case of repeated surgery they give a poor cosmetic effect 
and are inconsistent with oncological recommendations. 
Results of the fine- or core-needle aspiration biopsy 
or of the incisional (section) or shave biopsy do not de-
liver reliable data [according to recommendations of the 
American Joint cancer Committee/Union International 
Contre le Cancer (AJCC/UICC)] concerning the pri-
mary melanoma lesion and therefore should not be used. 
If the lesion is extensive and ulcerated, imprint cyto-
logy may be performed in order to obtain a sample for 
cytological examination (a glass slide should be pressed 
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recommendations of the American Society of 
Surgical Oncology (SSO), American Society of 
Clinical Oncology, and the European Society of 
Medical Oncology (ESMO) a sentinel node biopsy 
may be considered in melanoma pT1b and thick-
ness from 0.75 mm and coexistence of additional 
risk factors e.g. mitotic index ≥ 1/mm2 [III, A];
 — without clinical symptoms of metastases to the re-
gional lymph nodes or to the distant organs.
A sentinel node biopsy is obligatory to assess the 
presence of micrometastases in the lymph nodes [6]. 
During the sentinel node biopsy, a preoperative lym-
phoscintigraphy and a intraoperative lymphoscintigra-
phy combined with staining should be done. A sentinel 
node biopsy should be performed after the excisional 
biopsy of melanoma, simultaneously with the radi-
cal, wide local excision of the scar after the primary 
excisional biopsy of melanoma. Accessible data do not 
indicate any negative prognostic impact of performing 
the sentinel node biopsy six weeks after the excision 
of the primary melanoma site [III, B]. The accuracy of 
this method depends on the cooperation of a nuclear 
medicine specialist, surgeon, and pathologist. A sentinel 
node biopsy is a diagnostic procedure that is ‘minimally 
invasive’ due to low frequency of early and late com-
plications. 
All detected lymph nodes should undergo pathophysi-
ological assessment. If the metastatic deposits are mac-
roscopically visible it is enough to exam only one section 
while in all other cases serial sections of the lymph node 
at every 2–4 mm should be done. A histopathological 
report describing this material should include the number 
of lymph nodes found, the number of lymph nodes with 
metastases, the size and localisation of the biggest meta-
static site, the presence or absence of the extracapsular 
spreading, and vascular invasion. Immunohistochemical 
exam with use of specific markers (e.g. HMB45, Melan-A) 
may visualise tiny conglomerates of the neoplastic cells.
The results of the prospective study Multicentre 
Selective Lymphadenectomy Trial 1 (MSLT-1) suggest 
that a sentinel node biopsy melanoma helps to identify 
patients with high risk of metastases, helps to assess 
the clinical stage of the disease, ensures excellent local 
disease control, and enables qualification of patients to 
clinical trials with the use of homogenous criteria [7]. 
In the MSLT-1 trial in the whole analysed population 
of patients who underwent sentinel node biopsy, no 
disease-free survival time and no overall survival time 
improvement was proven, compared to the whole study 
population. However, in a subgroup of patients with 
present metastases to lymph nodes the overall 10-year 
survival rate was significantly better in patients in whom 
an immediate lymphadenectomy had been performed in 
the case of a positive sentinel node, compared to patients 
who had received this therapy later for clinically overt 
metastases (62.1% vs. 41.5%; p = 0.006) [7].
Figure 1. (According to W. Ruka) Recommended direction of 
the cut during the excisional biopsy. Spindle-shaped excision 
of the suspected pigmentary lesion should be made collaterally 
to the regional lymph vessel (toward the nearest draining 
lymph node/lymph vessel confluence), in the majority of cases 
enabling a primary suture of the wound
onto the tumour surface and then the material should 
be referred to cytological examination).
It is currently known that some defined subtypes 
of melanoma are associated with specific mutations 
(e.g. KIT gene mutations — subungual melanoma or 
mucosa melanomas). In patients with disseminated 
(primary or secondary) melanoma, testing for BRAF 
gene mutation in the fixed section is obligatory [and may 
also be reasonable in the case of high risk of relapse of 
melanoma (clinical stage IIIB, IIIC and IIID)] and for 
KIT and NRAS mutation is optional [V, A]. There is no 
need for repeated sampling of the metastases to detect 
the presence of molecular disorders. Genetic tests should 
be performed in referral centres that undergo quality 
audits. It is not recommended that mutations are tested 
for in patients with skin melanoma and no metastatic 
sites [4]. 
Sentinel node biopsy (microstaging II)
A sentinel node biopsy should be done in patients 
[II, A] [1, 3, 4, 7, 8]:
 — after an excisional biopsy and with histopathological 
confirmation of skin melanoma but not after a wide 
local excision of a primary site;
 — with Breslow thickness ≥ 1 mm:
•	 with (micro-) ulceration on the melanoma 
surface independently of the thickness of the 
infiltration [melanoma with primary site that has 
been classified as pT1b-T4b according to TNM 
UICC/AJCC 2010 classification]; according to 
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If the histopathological assessment affirms the pres-
ence of melanoma metastases to sentinel nodes, a radi-
cal lymphadenectomy may be considered (so-called 
completion lymph node dissection, CLND) because the 
melanoma metastases to other lymph nodes are detected 
by routine histopathological methods in about 20–30% 
of patients [9] (especially when micrometastasis size 
exceeds 1 mm). An alternative option is an observation 
with use of ultrasonographic monitoring of the regional 
lymphatic system every 4–6 months. The results of two 
published randomised studies [10, 11] did not prove 
any survival benefit in patients who had CLND due to 
a positive sentinel node biopsy. However, an improve-
ment in regional lymphatic basin control was achieved. 
Crucial prognostic value of the sentinel node biopsy was 
also confirmed in these studies. 
Actually, there are ongoing clinical studies evaluat-
ing if the adjuvant lymphadenectomy may be limited 
in some patients (sub-micrometastases to the sentinel 
lymph node with diameter < 0.1 mm or placed subcap-
sular and with diameter < 0.04 mm) with no negative 
impact on the melanoma reoccurrence rate [12].
Staging and risk factors
Identification of the clinical and pathomorphologi-
cal risk factors aims to understand the biology of the 
neoplasm and to plan a tailored therapy for a given 
patient, which considers relapse risk factors and overall 
survival probability. 
Risk (prognostic) factors
The primary melanoma lesion
The most important risk factors in patients with skin 
melanomas without metastases are thickness (Breslow) 
and presence of micro(ulceration) of the primary site. 
An important prognostic value of mitotic index and 
microsatellitosis as part of parameter N has recently 
been proven. These factors are included in TNM system 
version 8 (Table 3) [4–6, 13].
Metastases to the regional lymph nodes (clinical 
stage III)
The presence of metastases in the regional lymph 
nodes is the most important prognostic factor in pa-
tients with skin melanomas. In the case of the presence 
of metastases, the number of involved regional lymph 
nodes constitutes the principal risk factor. The type of 
metastases also influences the risk; patients with mi-
crometastases have better prognosis (neoplastic sites 
detected during the microscopic exam in the clinically 
not enlarged and not palpable lymph nodes — excised 
during the sentinel node biopsy) than patients with 
macrometastases (foci of neoplasm diagnosed during the 
microscopic exam in a clinically enlarged and palpable 
lymph node). Extracapsular infiltration of the neoplastic 
cells constitutes an additional negative risk factor in 
patients with metastases to the lymph nodes.
Metastases to the distant organs (clinical stage IV)
Localisation of metastases and LDH activity are 
the major prognostic factors in patients with extra-
nodal metastases.
Clinical staging — classification
The actual clinical and pathological stage classifica-
tion system of skin melanoma according to TNM was 
revised in 2010 and 2017, and formulated based on the 
multifactor analysis of data of 38,000 patients (Table 3) 
[13] [II, A].
Treatment
Surgery is a treatment by choice in patients with 
melanoma [I, A]. After performing an excisional biopsy 
of the suspected pigmented lesion and making a diag-
nosis of melanoma, we should consider a wide scar 
excision with appropriate margins and a sentinel node 
biopsy. In the case of detecting a metastasis in clinically 
palpable reginal lymph nodes by fine-needle biopsy, 
lymphadenectomy of the regional lymph nodes should 
be performed. Lymphadenectomy should be considered 
if a sentinel node biopsy confirms metastases. Actually, 
adjuvant therapy after surgery is used only in special 
situations, and in patients with metastatic disease it 
should be tailored to the clinical situation. The essential 
and obligatory recommendation is to refer patients to 
a multidisciplinary team of specialists experienced in 
diagnostics and treating melanomas.
Surgical treatment
Primary site
Radical therapy of the primary site of melanoma 
includes a radical wide excision of the scar after the 
excisional biopsy of the primary site.
Based on the results of six multicentre, randomised 
trials it was decided to derogate from extended excisions 
of the primary melanoma site (with margin ≥ 3 cm) in 
favour of narrower margins of healthy tissues. There 
are following actual recommended margins of radical 
therapy of the primary melanoma lesion (excision of the 
scare after excisional biopsy of the primary site): mela-
noma in situ — margin 5 mm, melanoma with tumour 
depth ≤ 2 mm — margin 1 cm, melanoma with tumour 
depth > 2 mm — margin 2 cm (Table 4) [II, A].
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Table 3. Clinical staging classification according to TNM AJCC/UICC from the year 2017
A. TNM system categories
Parameter T Breslow thickness [mm] (Micro-)ulceration
pTis (in situ)
T1 
   T1a
   T1b
≤ 1.0
< 0.8
< 0.8
0.8–1.0
Without ulceration
With or without ulceration
T2
   T2a
   T2b
> 1.0–2.00 Unknown or undetermined 
a) Without ulceration
b) With ulceration
T3
   T3a
   T3b
> 2.0–4.0 Unknown or undetermined 
a) Without ulceration 
b) With ulceration
T4
   T4a
   T4b
> 4.0 Unknown or undetermined 
a) Without ulceration 
b) With ulceration
Parameter N Number of the regional lymph nodes with metastases Presence of an in-transit 
metastasis, satellite sites  
and/or microsatellite***
Nx The status of the regional lymph nodes cannot be assessed No
N0 0 No 
N1
   N1a
   N1b
   N1c
One lymph node with metastatic transformation or presence of in-transit 
metastases satellite and/or microsatellite foci without involvement  
of the lymph nodes 
Metastasis to one lymph node detected by sentinel biopsy (micrometastasis*) 
Metastasis to one lymph node assessed by clinical exam (macrometastasis**)
No metastases to regional lymph nodes 
No
No
Yes
N2
   N2a
   N2b
   N2c
Micrometastases to 2 or 3 lymph nodes
Metastases to 2 or 3 lymph nodes, at least one clinically involved 
Metastasis to 1 lymph node (assessed by sentinel lymph node biopsy or 
clinically) 
No
No
Yes
N3
   N3a
   N3b
   N3c
≥ 4 lymph nodes or a conglomerate of lymph nodes or in-transit/ 
/satellite changes with coexisting metastases to at least lymph nodes
Micrometastases to at least 4 lymph nodes 
Metastases to at least 4 lymph nodes and at least one as clinically overt  
or conglomerate of lymph nodes 
Metastases to 2 or more lymph nodes and/or conglomerate of lymph nodes 
No
No
Yes
Parameter M Localisation of the metastases Serum LDH activity
M0 Without distant metastases 
M1a 
   M1a(0)
   M1a(1)
Skin, subcutaneous tissue or non-regional lymph nodes 
Normal
Increased 
Æ
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M1b
   M1b(0)
   M1b(1)
Lungs ± localisations M1a
Normal
Increased 
M1c
   M1c(0)
   M1c(1)
Other than above mentioned visceral organs with exclusion of central 
nervous system and ± localisations M1a and M1b 
 
Normal
Increased
M1d
 M1d(0)
 M1d(1)
Metastases to the central nervous system ± localisations M1a, M1b or M1c 
Normal
Increased
*Micrometastasis to the lymph node — detected by the microscopic exam of the clinically asymptomatic (not enlarged) lymph node, after performing the 
sentinel node biopsy; **macrometastasis to the lymph node — confirmed by the microscopic exam of the clinically palpable lymph node (enlarged) after 
a therapeutic lymphadenectomy; ***micro-/satellitosis — neoplastic infiltration or nodules (macro or microscopic) remoted up to 2 cm from the primary site 
of the skin melanoma to the level of the nearest regional lymph confluence/drainage; LDH — lactate dehydrogenase
B. Clinical stages 
Clinical stages* Pathological stages**
T N M T N M
0 Tis N0 M0 Tis N0 M0
IA T1a N0 M0 T1a
T1b
N0
N0
M0
M0
IB T1b
T2a
N0
N0
M0
M0
T2a N0 M0
IIA T2b
T3a
N0
N0
M0
M0
T2b
T3a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
T3b
T4a
N0
N0
M0
M0
IIC T4b N0 M0 T4b N0 M0
III*** Any T N1
N2
N3
M0
IIIA T1a/b–T2a N1a
N2a
M0
M0
IIIB T0
T1a/b–T2a 
T2b/T3a
N1b/N1c
N1b/c or 
N2b
N1a–N2b
M0
M0
M0
IIIC T0
T1a–T3a
T3b/T4a
T4b
N2b, N2c, 
N3b or N3c
N2c or 
N3a/b/c
Any N ≥ N1
N1a–N2c
M0
M0
M0
M0
IIID T4b N3a/b/c M0
IV Any T Any N Any M1 Any T Any N Any M1
*Clinical staging includes micrograding of the primary site and a clinical/radiological assessment of presence of metastases. Consequently, clinical staging 
may be applied only after complete excision of the primary site of the skin melanoma (excisional biopsy) and evaluation of the regional lymph nodes and 
distant organs for the presence of metastases; **pathologic grading/staging includes micrograding of the primary site and a pathological assessment of the 
regional lymph nodes: after a sentinel lymph node biopsy or after a radical lymphadenectomy (except from stage 0 and IA in which no procedure is applied 
to the regional lymph nodes); ***clinical staging does not include any subgroups of stage III
Table 3 cd. Clinical staging classification according to TNM AJCC/UICC from the year 2017
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Applying margins wider than 2 cm decreases the 
local reoccurrence rate but does not improve long-term 
survival. The scar after an excisional biopsy of a mela-
noma ≤ 2 mm should be removed without superficial 
fascia. These rules cannot be applied for melanomas 
located on the face, were no fascia are present and the 
excision margin may be narrower. In the case of the 
subungual localisation of melanomas, a distant phalanx 
should be amputated. 
Regional lymph nodes
Patients with melanoma with metastases to the re-
gional lymph nodes are a heterogenous group of patients 
considering the prognosis (five-year survival range: 
15–70%). Prospective clinical trials did not confirm any 
benefit of performing an elective lymphadenectomy in 
patients without clinical signs of melanoma metastases 
to the lymph nodes.  Currently, lymphadenectomy is re-
commended only in melanoma patients with confirmed 
metastases in sentinel lymph nodes (microstaging II) or 
when metastases are diagnosed by fine-needle biopsy 
(in special situations — surgical biopsy) of enlarged and 
clinically suspected lymph nodes [1, 3, 7, 14].
Therapeutic lymphadenectomy 
Qualification of patients for lymphadenectomy 
should be based on a clinical exam, laboratory test 
(including LDH serum level), and at least conventional 
chest radiogram and abdomen ultrasound. If the metas-
tases to distant organs are suspected a patient should 
have computed tomography or PET-CT (especially of 
the pelvis when metastases to the iliac and obturator 
lymph nodes are suspected) and MRI. Imaging exam 
of the central nervous system should be performed in 
the case of occurrence of clinical symptoms. 
The extent of the therapeutic lymphadenectomy in 
skin melanoma is as follows [III, C]: 
 — in the axilla all lymph nodes should be removed 
according to the anatomic definition [three groups 
of lymph nodes and the surrounding fascia: lower 
compartment — pectoral (anterior) and subscapu-
lar (lateral) lymph nodes, central compartment 
— central axillary lymph nodes, upper compart-
ment — infraclavicular (deltopectoral) and apical 
lymph nodes];
 — in the groin we should remove the lymph nodes of 
the inguinal-femoral lymph nodes located below the 
inguinal ligament in the femoral triangle together 
with the femoral fascia, iliac lymph nodes placed 
along the external iliac vessels (optionally also inter-
nal and common), as well as the lymph nodes of the 
obturator fossa (in the case of metastases diagnosed 
in the sentinel nodes the lymphadenectomy should 
be restricted to inguinal lymph nodes, 
 — in the cervical lymphatic confluence modified pro-
cedures may be applied. These procedures must be 
maximally radical. Usually the jugular structures 
that contain superficial lymph nodes (anterior and 
posterior) and profound in one piece, limited from 
behind by profound jugular facia and frontally by 
the platysma muscle. 
Sometimes it is necessary to perform lymphadenec-
tomy in the popliteal or ulnar fossa.
Local reoccurrence and in-transit metastases 
Terms: satellitosis (micro- or macroscopic), local re-
occurrence and in-transit metastases form a kind of con-
tinuity and represent different forms of one pathologic 
phenomenon. Usually a local reoccurrence (often even 
after a very wide excision of the primary site) represents 
spreading of melanomas through the regional lymphatic 
vessels (microsatellites become macrosatellites), which 
then may transform into in-transit metastases. That is 
why in the majority of elaborates the above-mentioned 
forms of relapse of melanoma are analysed together and 
have similar prognosis (10-year survival about 20–30%). 
Surgery is an essential method to treat a local relapse 
and in-transit metastases. Therapy should be individu-
alised and should consider the number metastases, their 
size, localisation, and clinical course [III, B]. In case of 
in-transit metastases surgical therapy includes excision 
of the countable changes (< 10) with a microscopic 
melanoma infiltration-free margin (it may be macro-
scopically narrow). In the case of a single relapse lesion 
another sentinel lymph node biopsy may be considered. 
In case of in-transit dissemination of melanoma limb 
amputation is not recommended. In case of multi-
ple/non-resectable lesions one of the local therapeutic 
methods should be considered (ablation, radiotherapy, 
cryotherapy), intratumoural immunotherapy (talimo-
gene laherparepvec-T-VEC, PV-10 or interleukin-2) or 
local immunotherapy (imiquimod is not registered for 
this indication) and electrochemotherapy [III, B]. In the 
case of extensive, multiple, lesions located on the limb 
an hyperthermic isolated limb perfusion chemotherapy 
is a method of choice [HILP], mostly with use of mel-
Table 4. Summary of the recommendations of the National 
Comprehensive Cancer Network (NCCN) v. 3.2016, 
European Organisation for Research and Treatment of 
Cancer (EORTC), and the European Society of Medical 
Oncology (ESMO) concerning the final margin of the radical 
excision of the primary melanoma site depending on the 
Breslow thickness
Melanoma thickness  
(Breslow)
Recommended clinical 
margin 
In situ 0.5 cm
≤ 2.0 mm 1 cm
> 2.0 mm 2 cm
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phalan. This method may be used only by experienced 
and trained centres. If HILP is contraindicated systemic 
therapy should be administered [1, 4, 5, 14–16].
Adjuvant therapy 
Actually, there are no recommendations concerning 
the routine use of systemic adjuvant therapy in clinical 
practice in patients after radical surgery of a primary lesion 
with lymphadenectomy. Adjuvant radiotherapy may be 
considered only in some, well-determined situations. Re-
sults of some recently published clinical studies indicate an 
improvement of survival rates after both adjuvant immu-
notherapy with use of immune checkpoint inhibitors and 
combined therapy with BRAF and MEK inhibitors [I, B].
High doses of interferon a-2b (INF a-2b) has been 
registered based on the positive result of one of three clin-
ical studies by the Easter Cooperative Oncology Group 
(ECOG) -ECOG 1684 — in the United States of America 
and in the European Community, to treat patients with 
melanoma in clinical stage IIB–III. Low dose INF a-2b 
has been registered in Europe for patients with clinical 
stage II melanoma [17, 18]. The registration was based 
on the significant prolongation of the overall survival 
during the seven-year observation time. These results 
have not been proven during a longer observation time 
(12 years). The results of the studies showed a repeatable 
(10 from 17 studies) improvement in the disease-free 
survival rates. The recent meta-analysis showed a signif-
icant decrease by 17–18% of the relative disease relapse 
risk after the administration of the adjuvant therapy with 
use of INF a-2b. The clinical evidence concerning overall 
survival rates is weaker and is based mostly on the results 
of meta-analyses. The overall five-year survival benefit 
for the whole group of patients reaches about 3–5%. The 
use of adjuvant therapy with INF a-2b in patients with 
intermediate and high relapse risk melanomas should be 
individualised due to its controversial clinical value and 
toxicity [II, B]. The result of meta-analyses shows that an 
adjuvant therapy with INF a-2b may be beneficial in pa-
tients with ulcerated primary melanoma lesion, especially 
with coexistent micrometastases (to the sentinel node 
but with absence of metastases to the clinically enlarged 
lymph nodes) [I, B] [19, 20].
Ipilimumab is registered in the United Stated for 
adjuvant therapy of patients after lymphadenectomy 
of involved regional lymph nodes. Randomised clini-
cal trials [21] showed a significant improvement of 
disease-free survival and overall survival but with high 
toxicity of ipilimumab therapy [II, B] [22]. 
A randomise clinical trial showed that patients 
with melanoma in clinical stage IIIB, IIIC, and IV, 
after lymphadenectomy, who received nivolumab, had 
by 10% improved one-year disease-free survival and 
lower toxicity compared to ipilimumab therapy [I, B]. 
Adjuvant therapy with dabrafenib and trametinib in 
patients with present BRAF gene mutation, clinical 
stage III, high-risk melanoma resulted in improvement 
of disease-free survival and overall survival compared 
to placebo [23]. These results suggest that all patients 
with melanoma in clinical stage II–IV should undergo 
a detailed, multidisciplinary examination.
Other methods of immunotherapy (e.g. interleu-
kin-2), vaccines, or cytotoxic drugs have no clinical value 
in the adjuvant, postoperative therapy of melanomas.
In some individual cases, after the surgical therapy 
of high-risk melanomas, an adjuvant radiotherapy 
(RT) may be applied. A dosing schedule includes, 
depending on the localisation of the melanoma lesion 
— hypofractionation, 3–8 Gy per fraction or conven-
tional fractioning. Indications for adjuvant radiotherapy 
after the primary tumour excision include: diagnosis of 
desmoplastic melanoma excited with narrow margins, 
presence of ‘positive’ surgical margins (especially after 
excision of the local reoccurrence), presence of satellite 
foci, significant neurotropism, or head and neck region 
localisation (solo RT may be used for extensive LMM 
lesions). In the case of excision of local reoccurrence 
and lymphadenectomy due to metastases to the regional 
lymph nodes, indications for adjuvant RT are: pres-
ence of extracapsular node infiltrations, involvement 
of ≥ 4 lymph nodes (clinical stage IIIC), diameter of 
a metastasis > 3 cm, detection of metastases to cervical 
lymph nodes (from two metastatic lymph nodes or when 
a metastasis measures at least 2 cm), and reoccurrence 
after prior resection [24, 25]. The results of the only 
completed randomised clinical trial assessing the value of 
adjuvant RT (48 Gy in 20 fractions) after lymphadenecto-
my in the case of high-relapse-risk melanoma, confirmed 
the improvement of local control in patients receiving 
radiation. RT had no impact on overall survival rate and 
resulted in a higher ratio of locoregional complications 
and deterioration of patients’ quality of life. These result 
suggest that use of adjuvant RT should be limited [II, C]. 
No adjuvant RT should be applied after CLND.
Therapy of patients with advanced disease 
The results of treatment of skin melanomas in clini-
cal stage IV are still unsatisfactory. The median overall 
survival time exceeds 12 months (and is significantly 
higher for new therapies) but about 20% of patient 
survive for five years. 
The significant prognostic factors in patients with 
melanoma in clinical stage IV are: performance sta-
tus, LDH activity, and localisation of the metastatic 
lesions. In the case of qualification of a patient with 
clinical stage IV melanoma for surgery or systemic 
therapy, disease should be staged by imaging exams or 
PET-CT (only in the case of isolated metastatic foci 
qualified for resection) [1].
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In the case of secondary changes to the skin, soft tis-
sues, and non-regional lymph nodes (M1a, better prog-
nosis), it is always recommended to consider excision. 
A similar approach should be applied for isolated (not 
necessarily single) metastases to the visceral organs. In 
the case of unresectable lesions, the choice of therapeu-
tic approach depends on the presence of metastases to 
the central nervous system (CNS). If the metastases to 
the CNS are present neurosurgical treatment and/or 
radiotherapy of the central nervous system (usually 
stereotactic or radiosurgery) should be considered as 
a first-line therapy (the decision depends on the location 
and number of lesions) in order to delay the occurrence 
of bleeding or neurological disorders. Radiotherapy of 
the central nervous system may be a part of combined 
therapy during immunotherapy (preferred) and during 
BRAF protein molecularly targeted therapy. RT is also 
used in palliative therapy in patients with metastases to 
soft tissues (ulceration, pain) and to bones (pain).
The advance in therapy of advanced melanoma, 
considering the low efficacy of cytotoxic agents, results 
from the use of nonspecific immunotherapy with use of 
monoclonal antibodies anti-CTLA4 or anti-PD1, which 
inhibit the systemic mechanisms of immunosuppression 
in order to induce an antineoplastic response (activation 
of lymphocytes T) as well as from the use of molecularly 
targeted therapies with use of serine-threonine kinases 
inhibitors. Patients with advanced melanoma should still 
be referred and screened to prospective clinical trials. 
Dacarbazine is the only registered cytotoxic drug for 
advanced melanoma. Its efficacy is limited (objective 
response rate — 15% of patients, median duration 
of response four months) [1, 3]. The only registered 
scheme of dacarbazine therapy is a five-consecutive-day 
schedule with a daily dose of 200 mg/m2; an alterna-
tive schedule of administering a higher dose of a drug 
(850–1000 mg/m2 every three weeks) has formally not 
been accepted; however, this alternative is considered 
useful in clinical practice. Paclitaxel in monotherapy or 
in combination with dacarbazine does not improve the 
duration of the response to the second-line therapy. 
Randomised trials in patients did not confirm higher 
efficacy of a polychemotherapy schedule including 
dacarbazine combined with cisplatin, vinca core alka-
loids (e.g. vinblastine) and nitrosamine derivates (e.g. 
carmustine) and tamoxifen. Use of biochemotherapy 
(chemotherapy combined with interleukin-2 and INF 
a-2b) does not improve melanoma patients’ overall 
survival rates compared to chemotherapy. The results 
of clinical studies indicate that interleukin-2 in mono-
therapy or combined with IFN a-2b slightly improves 
the overall response rate with no influence on the overall 
survival rate. The toxicity of this therapy is significant. 
Currently the use of chemotherapy should be limited 
to lifesaving situations after failure of the molecularly 
targeted therapies or immunotherapy [I, A].
Immunotherapy
Ipilimumab has been registered in the therapy 
of patients with advanced melanomas and resulted 
in-compared to peptide vaccine gp100 in a second-line 
therapy — significantly higher overall survival rates 
(a difference of about 3.5 months) with no impact on 
the disease-free progression time [26, 27]. Kinetics and 
time of response duration on ipilimumab therapy are 
different than for classical chemotherapy. The benefit 
of therapy is observed only after 3–4 months of therapy, 
which limits its application to patients with advanced 
melanoma with minimal symptoms, good performance 
status, and low disease course as well as (considering the 
safety profile) to patients with no autoimmune diseas-
es. Due to late objective response occurrence, a reliable 
evaluation of the efficacy of ipilimumab therapy should 
be done after 12 weeks of treatment. Moreover, in the 
early phase of the therapy a phenomenon of paradoxi-
cal progression due to infiltration of the tumours by the 
immunocompetent cells may occur. The immunological 
response criteria should be applied in order to get objec-
tive imaging examination evaluation of the ipilimumab 
efficacy [26–28]. Currently there are no known predic-
tive factors of response to ipilimumab. A recommended 
dosing schedule is 3 mg/kg of body weight, administered 
every three weeks up to four doses [I, A].
The objective overall response rate to ipilimumab 
therapy is low (about 10%), and long-term benefits are 
observed in a limited number of patients (20–25%); how-
ever, they are characterised by long-lasting responses 
(the longest observation reaches 10 years). Adverse 
events related to autoimmunological reactions con-
stitute a major problem of ipilimumab therapy (grade 
3–4 adverse events occur in about 20–25% of patients). 
The most common immunological adverse events in-
clude: skin changes, diarrhoea, hepatotoxicity, and en-
docrinopathies (including insufficiency of pituitary and 
thyroid gland). Occurrence of these syndromes in a pa-
tient treated with ipilimumab should result in an urgent 
referral of this patient to a medical centre experienced 
in treating complications of immunotherapy. In the case 
of intensified symptoms that disenable transportation, 
corticosteroids should be immediately administered 
[dexamethasone (or equivalent) 1–2 mg/kg of body 
weight], and further therapy should be applied in col-
laboration with/with assistance of a referral centre. The 
appropriate algorithms of proceeding are accessible [27] 
and should be rigorously implemented from the mo-
ment of the occurrence of first symptoms suggesting 
immunological toxicity. 
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Ipilimumab therapy should be applied only in ter-
tiary referral centres that provide holistic diagnostic 
and therapeutic proceedings. It is not recommended to 
start this therapy in inexperienced centres with limited 
therapeutic options.
Currently, immunotherapy in skin melanomas is 
mostly related to the usage of immune control check-
points PD-1 in monotherapy (nivolumab 3 mg/kg of 
body weight every two weeks or pembrolizumab 2 mg/kg 
of body weight every three weeks) [29–31] [I, A] or in 
combination with anti-CTLA-4 antibodies [32] [I, B]. 
These agents have been proven in clinical practice, in 
monotherapy or in combination with ipilimumab, to 
give long-lasting clinical benefit in some patient with 
advanced melanomas and significant response rates 
(reaching 50%) and one-year survival rates of 70–80%. 
The use of nivolumab or pembrolizumab results in 
two-year survival rates of 50–60% (median survival ex-
ceeds two years, three-year survival rate reaches about 
45%), with acceptable toxicity (about 15% in grade 3/4, 
which is significantly less than for ipilimumab); however, 
the most severe symptom also results from autoimmune 
toxicity. Clinical studies confirmed a higher efficacy of 
pembrolizumab concerning the overall survival and 
disease-free survival time compared to ipilimumab in 
first-line therapy, and compared to chemotherapy after 
failure of prior therapy [29–31]. In recently published 
results of a clinical trial which compared efficacy of 
nivolumab in monotherapy, ipilimumab in mono-
therapy, and a combination of both drugs, nivolumab 
revealed to be more effective than ipilimumab (the 
median disease-free survival time reached respectively 
6.9 vs. 2.9 months); however, the combination of both 
drugs had the highest efficacy (the median disease-free 
survival was 11.5 months). The combination therapy was 
the best option in the case of low PD-L1 expression in 
the neoplastic tissue (< 5%). In the case of high PD-
-L1 expression (> 5%) the results of nivolumab therapy 
in monotherapy or in combination with ipilimumab were 
comparable, and similarly overall survival results [32]. 
The results of combined ipilimumab and nivolumab 
therapy were also better when a BRAF gene mutation 
was present; however, in the whole group of patients 
[33] the improvement in three-years survival rates in 
the combination therapy arm compared to monotherapy 
with nivolumab reached only 6%: 58% vs. 52%, respec-
tively. The adverse events in Common Terminology 
Criteria for Adverse Events (CTCAE) grade 3–4 were 
significantly more frequent in the combined therapy arm 
(56.55%) compared to 19% in nivolumab and 27% in 
the ipilimumab arm. 
In the clinical study a therapy with anti PD-L1 anti-
body, pembrolizumab, was maximally continued for two 
years. In the group of 104 patients who accomplished the 
two-year therapy period, 102 persons (98%) are still alive 
while the nine-month disease progression-free survival 
rate reached 91% (which means that in the majority of 
patients disease control is maintained even when the 
active therapy had been stopped) [II, B] [34].
In light of the presented results of the clinical studies, 
ipilimumab should not constitute an essential type of 
immunotherapy in patients with advanced melanomas 
because it is less efficient than anti PD-L1 antibodies and 
has a worse safety profile. The therapy should be started 
from anti PD-L1 (nivolumab or pembrolizumab) in 
monotherapy [I, A]. The issue of combined therapy with 
anti-CTLA-4 antibodies requires further investigation. 
Molecularly targeted therapy
The presence of mutation of the RAS/RAF/MEK/ERK 
MAP kinase pathway is detected in 75% of skin can-
cers. The major mechanism leading to hyperactivity of 
RAS/RAF/MAPK pathway I skin melanoma is a muta-
tion of a kinase BRAF encoding gene mutation. Somatic 
mutations in BRAF gene are observed in 50–70% of 
skin cancers occurring on the skin areas not exposed to 
long-term solar radiation. Published in year 2011, the 
results of the registration phase III study of vemurafenib 
use in first-line therapy in patients with present BRAF 
V600 mutation showed 48% overall response to thera-
py rate in patients receiving BRAF inhibitor (BRAFi) 
compared to 5% in patients on dacarbazine, as well as 
significant improvement of disease progression time 
(five months difference) and of overall survival (three 
months difference) [35]. Vemurafenib has been regis-
tered to treat patients with advanced melanoma with 
presence of BRAF mutation (testing for this mutation is 
possible in Polish centres with use of a validated test) [I, 
A]. Even though in the majority of patients resistance to 
therapy will develop (median disease progression-free 
survival totals 6–7 months), the results of phase II–III 
revealed a 13–16-month long median overall survival 
time, in patients with metastatic melanoma, which is 
significantly better than any other reported survival 
benefit in this subset of patients. Vemurafenib is char-
acterised by significant skin toxicity (hypersensitivity 
to UV radiation), hepatotoxicity typical for kinase 
inhibitors, and by formation of secondary neoplasms 
(cancer or keratoacanthoma of the skin in about 20% 
of treated patients). The secondary skin neoplasms 
may develop within a few weeks after the onset of the 
therapy with vemurafenib. Diagnosis of secondary skin 
cancers requires local therapy but not interrupting the 
drug. The adverse events quite often require reduction 
of vemurafenib dose. In the year 2012 a therapeutic 
efficacy of another BRAF inhibitor, dabrafenib, was 
proven (characterised by efficacy similar to vemurafenib 
but by a different toxicity profile, e.g. lower skin toxici-
ty). The median disease progression-free time reached 
6.7 months for dabrafenib vs. 2.9 months for dacar-
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bazine, whereas the median overall survival time on 
dabrafenib therapy reported in the year 2013 reached 
18.2 months [36] [I, A]. In a phase III trial, the efficacy 
of MEK inhibitor (MEKi) has also been confirmed tra-
metinib — in patients with metastatic melanomas with 
present BRAF gene mutations [37] [I, B]. The efficacy 
of MEK inhibitors has also been observed in patients 
with NRAS gene mutations [38]. The results of recent 
studies (COMBI-d, COMBI-v, and coBRIM) showed 
that in patients with metastatic melanomas with present 
BRAF gene mutation the use of combination of BRAF 
and MEK inhibitors (dabrafenib and trametinib or ve-
murafenib with cobimetinib) yields better results than 
monotherapy and no increase of toxicity [39–43] [I, A]. 
The median overall survival time on the combination of 
both drugs was improved to about 23–25 months and 
median disease progression time of 12 months. The 
best overall survival is achieved in patients with normal 
LDH activity and serum concentration and less than 
three organs involved with metastases. Both drug com-
binations are currently accessible in Poland in the Drug 
Program in the first- or second-line therapy in patients 
with advanced melanoma with confirmed presence of 
BRAF V600 mutation. 
The above-mentioned drugs have a beneficial influ-
ence also in patients with stable and/or asymptomatic 
metastases to the brain, and until now this localisation 
was inaccessible for the systemic therapy of melanoma 
patients with melanoma and BRAF gene mutation, in 
whom asymptomatic brain metastases have been detect-
ed may receive a first-line therapy with BRAF inhibitor 
(in combination with MEK inhibitor).
A new option of the molecularly targeted therapy is 
to restart the combined therapy with BRAF and MEK 
inhibitors after this therapy has been stopped due to 
a disease progression. A phase II study revealed that 
restarting a therapy with dabrafenib and trametinib 
resulted in partial remission in 8 of 25 patients (32%) 
and in stabilisation of the disease in another 40% of 
patients. The median disease progression-free time to 
so-called ‘rechallenge’ reached 4.9 months [44]. The 
analysis of data of 116 patients with advanced mela-
noma, who had received therapy with BRAF inhibitor, 
progressed and received another therapeutic modality, 
and then were restarted on combined therapy with 
BRAF ± MEK inhibitor was presented at the ASCO 
meeting in 2017. The median time of treatment duration 
was 9.4 and 7.7 months for the primary and reused mo-
lecularly targeted therapy, respectively. After restarting 
the use of BRAF ± MEK inhibitors the response rate 
was 43%: complete responses rate 3%, partial responses 
rate 39%, stabilisation of the disease 24%, and pro-
gression of the disease 30% (no data 4%). The median 
overall survival time form the restart of the therapy 
reached 9.8 months [II, B] [45]. 
BRAF inhibitors (+MEK inhibitors) induce 
a prompt response and neoplasm control in the major-
ity of patients with advanced melanomas with present 
BRAF gene mutation. However, the response duration is 
limited due to activation of mechanisms of resistance to 
therapy. Due to these characteristics this therapy should 
be considered as a treatment of choice in patients with 
symptomatic disease and/or big tumour mass. There 
are no final data concerning the optimal sequence of 
immunotherapy and molecularly targeted therapy in 
patients with melanomas with presence of BRAF gene 
mutation. However, the activity of BRAF inhibitor is 
maintained after immunotherapy and of immunotherapy 
(anti-PD-L1) after treatment with inhibitors. In rare 
cases of patients with melanomas carrying some KIT 
gene mutations, the activity of KIT kinase inhibitors 
has been observed [40] [II, B].
Follow-up after therapy completion 
The frequency and type of control examinations as 
well as duration of the observation should be established 
based on the individual disease relapse risk (which 
depends on the initial clinical stage of the disease). 
However, we should bear in mind that the relapse may 
occur even 10 years after the primary treatment [46, 
47] (Table 5). The relapse risk is the highest in the first 
three years post therapy. That is why it is recommended 
to apply in this period a more intense schedule of con-
trol exams in order to detect a loco-regional relapse, 
which may be cured by surgery. Assessment of scars 
post primary site excision and post lymphadenectomy 
constitutes the most important part of the observation. 
The evaluation of the regional lymph confluence should 
be done carefully (a possible in-transit dissemination). 
To evaluate the local lymph nodes we may use palpation 
and ultrasonography. A patient may detect a majority of 
loco-regional relapses and that is why he/she should be 
trained to make a self-control of the area of the mela-
noma excision and of the regional lymph nodes. There 
are some premises that a less intensive control schedule 
has no negative impact on the survival in patients with 
early melanomas. 
Imaging exams are not recommended in asympto-
matic patients with clinical stage IA–IIA. Imaging exams 
(e.g. CT exam) may be considered in asymptomatic 
patients with clinical stage IIB–IIIC during the first 
2–3 years of follow-up (taking into consideration the 
availability of some new, effective drugs in the therapy 
of disseminated melanomas. The earlier data evaluat-
ing the intensive schedule of the control imaging exams 
demonstrated only a minimal benefit — maximally two 
months prolongation of the overall survival time). Then, 
in patients with clinical symptoms suggesting the pres-
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Table 5. Exams recommended in monitoring melanoma patients
Clinical stage of melanoma                               Type of exam Frequency of control exams
Early melanomas after the 
excision of the primary site 
without any metastases to the 
lymph nodes (clinical stages 
IA–IB)
Physical examination and anamnesis, especially a careful 
examination of the whole skin surface and of the regional 
lymph nodes as well as of the area of the scare post excision 
of melanoma
Radiologic image (RT) of the chest — optionally 
Other exams (e.g. US, CT) in the case of presence of 
suspected symptoms
Ultrasound of regional nodes when no sentinel node biopsy 
has been performed, in skin melanomas ≥ pT1b
There are no indications for any additional test except form 
physical exam in patients post excision of melanoma pT1a
Patients should be trained to perform a self-control 
examination
Every 6–12 months during the 
first 5 years, then once a year 
(follow-up may be done outside 
the specialist centre)
Locally advanced melanomas 
post excision of the primary site 
without metastases to regional 
lymph nodes (clinical stages 
IIA–IIC)
Physical examination and anamnesis, especially a careful 
examination of a whole skin surface and of the regional 
lymph nodes as well as of the area of the scare post excision 
of melanoma
Radiologic image (RT) of the chest, ultrasound of the 
abdomen
Blood morphology and biochemistry (liver tests and activity 
of lactate dehydrogenase) — optionally 
Other tests (e.g. CT) in the case of presence of suspected 
symptoms 
Ultrasound of regional nodes when no sentinel node biopsy 
has been performed, in skin melanomas ≥ pT1b
In patients with clinical stage IIB–IIC a CT exam may be done 
every 6–12 months and optionally MRI of CNS once a year 
(during the first 2–3 years)
Patients should be trained to perform a self-control 
examination. In clinical stage IIC more intensive monitoring 
schedules may be used as in clinical stage III
Every 3–6 months during 
first 2–3 years, then every 
6–12 month during next 5 years 
and then once a year
Post excision of the metastases 
to the regional lymph nodes 
or of a local relapse/satellite or 
in-transit lesion (clinical stages 
IIIA–IIIC)
Physical examination and anamnesis. Especially a careful 
examination of a whole skin surface and of the regional 
lymph nodes as well as of the area of the scare post excision 
of melanoma
Radiologic image (RT) of the chest
Blood morphology and biochemistry (liver tests and activity 
of lactate dehydrogenase) — optionally
Ultrasound of abdomen and eventually of the regions of the 
removed lymph nodes
CT exam of the chest, abdomen and pelvis every 
6–12 months and optionally in clinical stage IIIC, once 
a year a MRI of the brain (during the first 3 years)
Patients should be trained to perform a self-control 
examination
Every 3–4 months during the 
first 2 years, every 3–6 month 
during the next 3 years and then 
once a year
After therapy of distant 
metastases (clinical stage IV)
Evaluation of the imaging exams depending on the 
localisation of the measurable metastatic sites
Serum activity of LDH
An individual monitoring 
schedule for each patient
US — ultrasonography; RT — radiological exam; CT — computed tomography; MR — magnetic resonance; LDH — lactate dehydrogenase
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Figure 2. A schedule of diagnostic and therapeutic recommendation in patients with skin melanoma
ence of distant metastases (liver enzymes elevation, bone 
pains, neurological symptoms, cough, and weakness) 
detailed imaging diagnostics should be done, with CT, 
MRI, and scintigraphy included. 
256
OncOlOgy in clinical practice 2017, Vol. 13, No. 6
Figure 3. Recommended schedule of systemic therapy in patients with advanced melanoma in clinical stage IV or unresectable III
During the control exams we should carefully check 
not only the area of the primary melanoma lesion but 
also the whole skin surface. Melanoma patients have 
a statistically higher risk of developing a lesion of mela-
noma or of anther skin cancer. 
Summary
The excisional biopsy of the suspected pigmented 
moles, which may be early melanomas, is essential 
to diagnose and assess the main risk factors of mela-
noma (microstaging I). Early diagnosis and removal 
of melanoma not only improves the prognosis but also 
give a chance of cure in nearly 90% of patients. Usually 
the pigmented changes with transversal axis dimensions 
not exceeding 2 cm may be removed in an outpatient 
clinic during an excisional biopsy. The next stages of 
the proceedings include qualification of a patient to 
a radical, wide scar excision with appropriate surgical 
margins and to sentinel node procedure. In the case 
of clinical metastases to the regional lymph nodes 
a radical lymphadenectomy is a method of choice. It is 
recommended that patients with high-risk melanoma 
be included in prospective clinical trials evaluating the 
adjuvant therapy. A schedule of diagnostic and thera-
peutic recommendations in patients with skin melanoma 
is shown in Figures 2–4.
The presence of distant metastases is still associated 
with poor prognosis. It is recommended that patients 
with generalised disease be treated in clinical tri-
als. BRAF mutation should be tested in all patients with 
advanced disease or with high disease relapse risk [III]. 
Long-term survival is seen mostly in patients in clinical 
stage IV, who have had resection of singular metastatic 
lesions. In patients with present BRAF V600 gene mu-
tation, mostly in first-line therapy, a BRAF inhibitor 
may be used (preferentially in combination with MEK 
inhibitor). Immunotherapy with anti PD-1 antibodies 
(nivolumab or pembrolizumab) or eventually ipili-
mumab (anti-CTLA-4 antibody in monotherapy or in 
combination with anti-PD-1) may be used independently 
of the BRAF mutation presence. The optimal sequence 
of therapy (especially in the case of BRAF mutation) has 
not been assessed. The use of combined therapy with 
BRAF and MEK inhibitors involves a high response 
rate (about 70%) and rapid alleviation of symptoms of 
the disease. Therapy with anti-PD-1 antibodies results 
in lower response rates, but in the majority of patients 
the response is durable.
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Figure 4. Recommended schedule of systemic therapy in patients with advanced melanoma in clinical stage IV or unresectable III 
with present BRAF gene mutation
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